An
article published this year in the “Clinical
Immunology”
using one of our products, “FITC
Mouse Anti-Human CD56”, by our customers from Egypt, in the analysis of how Modulation the
expression of natural killer cell activating receptor (NKp44) in the peripheral
blood of diffuse large B-cell lymphoma patients and the correlation with clinic
pathological features. Congrats and Thanks.
Summay:
NK cell activation is one strategy to improve the
immunotherapy of non-Hodgkin's lymphoma. So, we aimed to investigate expression
of Natural killer cell activating receptor NKp44 in patients with diffuse large
B-cell lymphoma (DLBCL) and its correlation with clinic pathological data. In
this study, 30 new cases with DLBCL in addition to 20 healthy control were
involved. All were submitted to full history, clinical examination,
histopathology, Routine laboratory investigations including CBC, LDH, β2microgloubine and bone marrow examination. Cell
culture of peripheral blood mononuclear cells and expression of CD56 and NKp44
by flowcytometry was done. We demonstrated increased NK cell populations (CD 56
+ ve NKp44 –ve, CD 56 –veNKp44 + ve, total CD 56 + ve) and NKp44
MFI after in-vitro activation in both healthy control and DLBCL cases except
for CD 56 + ve NKp44 + ve which significantly increased in patients
not in healthy control (p = 0.005, 0.601) respectively. No
significant difference between the DLBCL and healthy control regarding all NK
cell populations without PHA stimulation. However, the culture with PHA in
DLBCL showed significant increase in NK cell populations than the healthy
control (CD 56 + ve NKp44 + ve 12.37 ± 7.52vs 6.80 ± 4.07,
p = 0.008), (Total CD 56 + ve 18.80 ± 8.74vs
12.66 ± 5.17, p = 0.017), (MFI of NKp44
10.95 ± 6.18vs 5.58 ± 1.70, p = 0.001). Regarding
the association with clinic pathologic features, increased expression of NKp44
was associated with lower values of LDH and earlier stages of DLBCL
(p < 0.05). So, activating receptor NKp44 can be modulated by
in-vitro activation, hence improvement of its function as an approach of
immunotherapy of DLBCL.
a: flowcytometric analysis of CD56 and NKp44 expression in control without PHA stimulation. b: flowcytometric analysis of CD56 and NKp44 expression in control with PHA stimulation.
Reference:
Product link:
FITC Mouse anti-Human
CD56
No comments:
Post a Comment